戻る Agenda
Keynote Address: Research Integrity in the Quest for Therapies for Alzheimer’s Disease
Session Chair(s)
Annette S. Williams, MBA, RPh
Vice President, Pharmacovigilance
IQVIA, United States
This session will present the history of experimental anti-amyloid therapies for Alzheimer’s disease in the context of recent revelations regarding potential research integrity concerns underlying assumptions of the amyloid cascade hypothesis. This case will illustrate the persistent corruptive influence of research misconduct on the evolution of a field of study. The session will close with a discussion of the responsibilities of co-authors, funders, publishers, and regulatory bodies on maintaining high standards of integrity and strategies to limit the damage from unreliable data sources.
Learning Objective : - Recognize risk factors for research misconduct and strategies for mitigating influence of unreliable data sources
- Formulate approaches to misconduct concerns that mitigate collateral damage while ensuring deep commitment to data integrity
- Propose strategies to lower the risk of research misconduct and influence of inaccurate data sources in collaborative research
Speaker(s)
Keynote Speaker
Matthew Schrag, MD, PhD
Vanderbilt University Medical Center, United States
Assistant Professor of Neurology & Director, Cerebral Amyloid Angiopathy Clinic